Kalaris Therapeutics, Inc. (KLRS): Nasdaq/NYSE listing notice — AlloVir receives Nasdaq notice of non-compliance; bid price below $1.00 for 30 days

Kalaris Therapeutics, Inc.

Received Nasdaq letter on Feb 9, 2024, for bid price < $1.00 over 30 consecutive business days.
Has 180 days (until Aug 7, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant, may get additional 180 days if certain criteria are met.
Evaluating options including reverse stock split to regain compliance.
Common stock continues trading on Nasdaq Global Select under symbol ALVR for now.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Kalaris Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 9, 2024, AlloVir, Inc. (“AlloVir”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of AlloVir’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, AlloVir is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of AlloVir’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-032160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.